Biogen (BIIB) EPS (2009 - 2026)
Biogen (BIIB) EPS from Jun 30, 2009 to Mar 31, 2026. The TTM Biogen (BIIB) EPS is $11.33. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EPS
Quarterly EPS
Biogen (BIIB) EPS CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +16.40% |
| 3 Years TTM | -18.35% |
| 5 Years TTM | -10.40% |
| 10 Years TTM | -2.52% |
| All Time TTM | +7.97% |
Annual EPS change of Biogen (BIIB)
| Year | EPS | Change |
|---|---|---|
| 2026 | $2.17 | -75.36% |
| 2025 | $8.81 | -21.33% |
| 2024 | $11.19 | +39.71% |
| 2023 | $8.01 | -62.13% |
| 2022 | $21.16 | +99.88% |
| 2021 | $10.59 | -59.67% |
| 2020 | $26.25 | -22.34% |
| 2019 | $33.80 | +50.45% |
| 2018 | $22.47 | +87.15% |
| 2017 | $12.01 | -30.00% |
| 2016 | $17.15 | +5.70% |
| 2015 | $16.23 | +29.71% |
| 2014 | $12.51 | +58.75% |
| 2013 | $7.88 | +35.09% |
| 2012 | $5.83 | +14.41% |
| 2011 | $5.10 | +22.00% |
| 2010 | $4.18 | +333.50% |
| 2009 | $0.96 | -64.54% |
| 2008 | $2.72 | N/A |
Comparison Biogen (BIIB) five years EPS CAGR with competitors
Biogen (BIIB) five years EPS CAGR is -15.32%.
| Ticker | Name | five years EPS CAGR | Upside |
|---|---|---|---|
| GILD | Gilead Sciences Inc | 98.59% | -743.57% |
| LLY | Lilly(Eli) & Company | 29.14% | -290.23% |
| NVO | Novo Nordisk | 24.26% | -258.34% |
| AZN | Astrazeneca plc | 17.09% | -211.58% |
| NVS | Novartis AG | 14.96% | -197.65% |
| JNJ | Johnson & Johnson | 11.59% | -175.65% |
| BMY | Bristol-Myers Squibb Company | 5.08% | -133.18% |
| GSK | GSK Plc | 4.65% | -130.37% |
| MRK | Merck & Co Inc | 4.39% | -128.65% |
| AMGN | AMGEN Inc | 3.49% | -122.81% |